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Abstract
Objective: Invariant natural killer T (iNKT) cells regulate collagen-induced arthritis (CIA) when activated by their potent
glycolipid ligand, alpha-galactosylceramide (a-GalCer). Glucose-6-phosphate isomerase (GPI)-induced arthritis is a closer
model of human rheumatoid arthritis based on its association with CD4+ T cells and cytokines such as TNF-a and IL-6 than
CIA. Dominant T cell epitope peptide of GPI (GPI325-339) can induce arthritis similar to GPI-induced arthritis. In this study,
we investigated the roles of activation of iNKT cells by a-GalCer in GPI peptide-induced arthritis.
Methods: Arthritis was induced in susceptible DBA1 mice with GPI peptide and its severity was assessed clinically. The
arthritic mice were treated with either the vehicle (DMSO) or a-GalCer. iNKT cells were detected in draining lymph nodes
(dLNs) by flow cytometry, while serum anti-GPI antibody levels were measured by enzyme-linked immunosorbent assay. To
evaluate GPI peptide-specific cytokine production from CD4+ T cells, immunized mice were euthanized and dLN CD4+ cells
were re-stimulated by GPI-peptide in the presence of antigen-presenting cells.
Results: a-GalCer induced iNKT cell expansion in dLNs and significantly decreased the severity of GPI peptide-induced
arthritis. In a-GalCer-treated mice, anti-GPI antibody production (total IgG, IgG1, IgG2b) and IL-17, IFN-c, IL-2, and TNF-a
produced by GPI peptide-specific T cells were significantly suppressed at day 10. Moreover, GPI-reactive T cells from mice
immunized with GPI and a-GalCer did not generate any cytokines even when these cells were co-cultured with APC from
mice immunized with GPI alone. In vitro depletion of iNKT cells did not alter the suppressive effect of a-GalCer on CD4+ T
cells.
Conclusion: a-GalCer significantly suppressed GPI peptide-induced arthritis through the suppression of GPI-specific CD4+ T
cells.
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Introduction
Rheumatoid arthritis (RA) is a chronic polyarthritic inflamma-
tory disease of the synovial membranes. Although the etiology of
RA is considered to be an autoimmune reactivity to certain self
antigens, the exact mechanism remains obscure. Accumulating
evidence suggests that CD4+ helper T cells play an important role
in the pathogenesis of RA [1]. Invariant natural killer T (iNKT)
cells are a unique subset of T cells that co-expresses NK markers,
such as NK1.1 and a highly restricted TCR repertoire, composed
of a single invariant a chain (Va14-Ja18 in mice and Va24-Ja18
in humans), together with a limited TCR Vb repertoire. When
iNKT cells recognize glycolipid ligands presented by the class I
major histocompatibility complex (MHC)–like molecule CD1d on
antigen presenting cells (APCs), they rapidly respond by producing
large amounts of Th1, Th2, and Th17 cytokines [2–4]. The potent
exogenous ligand of iNKT cells, a-galactosylceramide (a-GalCer),
has been used for the treatment of several types of murine
autoimmune models such as type 1 diabetes, experimental
autoimmune encephalomyelitis (EAE), and collagen-induced
arthritis (CIA) [5–9]. The effects of a-GalCer on these autoim-
mune diseases are considered to be mediated through the
induction of antigen-specific IL-10 production [8,10], foxp3+
regulatory T (Treg) cells [11,12], and regulatory dendritic cells
[13]. However, the role of a-GalCer in various autoimmune
diseases, including RA, remains to be elucidated.
Glucose-6-phosphate isomerase (GPI) is an arthritogenic
autoantigen identified in KxB/N mice [14]. GPI can provoke
arthritis in susceptible DBA1 mice [15]. GPI-induced arthritis is
considered to be a closer model of human RA than CIA with
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regard to its dependency on CD4+ T cells and response to
biological agents, such as anti-TNF-a and anti-IL-6 receptor
antibody [16,17]. GPI-induced arthritis is characterized by early-
onset of clinical signs of arthritis, which usually develop around
day 8, with an early peak on day14. We and Bruns et al.
demonstrated previously that the major epitope of T cells in GPI-
induced arthritis is human GPI325–339, and that immunization
with the 15-mer peptide can provoke GPI peptide-induced
arthritis, which is similar to GPI-induced arthritis [18,19].
The present study is an extension to our previous studies on the
role of a-GalCer in GPI peptide-induced arthritis. The results
showed that a-GalCer activated iNKT cells and provided
protection against GPI peptide-induced arthritis. The results also
showed that a-GalCer suppressed GPI-specific CD4+ Th1 and
Th17 cell response and anti-GPI autoantibody production by B
cells. Thus, in the T cell dependent arthritis model, a-GalCer
seems to suppress arthritis through antigen-specific regulation,
suggesting a potentially useful therapeutic strategy against human
RA through iNKT cell ligands.
Materials and Methods
Mice
Male DBA/1J mice were purchased from Charles River Japan
(Tokyo, Japan). The animals were kept under specific pathogen-
free conditions in our animal facility and studied at 7–10 weeks of
age. The Institutional Animal Care and Use Committee of the
University of Tsukuba approved all the experimental protocols
(Permit number: 2010–116 and 2011–119). All the surgery was
performed under isoflurane anesthesia, and all the efforts were
made to minimize suffering.
Reagents
a-GalCer was purchased from Funakoshi (Tokyo, Japan). The
stock solution of a-GalCer was dissolved in 100% dimethyl
sulfoxide (DMSO) at 1 mg/ml and diluted in phosphate-
buffered saline (PBS) just before injection. The following
monoclonal antibodies (mAbs) were used for flow cytometric
analysis: fluorescein isothiocyanate (FITC)-conjugated anti-CD4
(clone: RM4–5; Biolegend, San Diego, CA), alexa 488-
conjugated foxp3 (clone: MF-14; Biolegend), phycoerythin-
cyanine- 5 (PE/Cy5)-conjugated TCRb (clone: H57–597;
Biolegend), PE/Cy5-conjugated CD3 (clone; 145–2C11; Biole-
gend), allophycocyanin (APC)-conjugated CD19 (clone: 6D5;
Biolegend), APC-conjugated CD25 (clone: PC61; Biolegend),
and PE-conjugated CD1d-tetramer (MBL International, Wo-
burn, MA). For the loading of CD1d-tetramer, the stock
solution of a-GalCer was dissolved in pyridine at 1 mg/ml.
Prior to use, a-GalCer was diluted to 0.2 mg/ml with 0.9%
NaCl and 0.5% polysorbate-20. PE-conjugated CD1d tetramer
was loaded overnight with a-GalCer at a ratio of 20:1 at room
temperature. Recombinant human GPI was prepared as
described previously. GPI peptide was synthesized with 90%
purity by Invitrogen (Carlsbad, CA) as described previously
[18].
Figure 1. a-GalCer significantly suppressed the severity of GPI peptide-induced arthritis. DBA1 mice were immunized with GPI peptide
and then treated with either DMSO (as a vehicle control) or a-GalCer followed by clinical assessment of arthritis. (n = 5, data shown are representative
results of three experiments). (A) Severe swelling of ankle joints of control mice and markedly improved swelling of the ankle joints of a-GalCer-
treated mice. (B) Clinical score, and (C) Ankle thickness. The latter represented the severity of arthritis. Arrow indicates a-GalCer administration. Data
are mean6SD. *p,0.01, by Man-Whitney test.
doi:10.1371/journal.pone.0051215.g001
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GPI Peptide-induced Arthritis and Treatment with
Glycolipids
GPI peptide was dissolved in DMSO. Prior to use, GPI peptide
in DMSO was dissolved in Ringer solution to appropriate volume.
Mice were immunized intradermally with 10 mg of GPI peptide in
complete Freund’s adjuvant (CFA) (Difco, Detroit, MI). GPI
peptide and CFA were emulsified at a 1:1 ratio (volume/volume).
For induction of arthritis, 150 ml of the emulsion was injected
intradermally into the base of the tail. On days 0 and 2 after the
immunization, 200 ng of pertussis toxin (Sigma-Aldrich, St. Louis,
MO) was injected into mice intraperitoneally to develop arthritis.
Mice were then treated with DMSO (vehicle control of a-GalCer)
or 2 mg of a-GalCer on day 0 (with GPI peptide and CFA) or day
10 (with CFA). All the a-GalCer treatments were single and
intradermal injections. Arthritis was evaluated visually, and
changes in each paw were scored on a scale of 0–3, as described
previously [17].
Detection of Anti-GPI-antibody
Sera were obtained on day 28 and analyzed for the existence of
anti-GPI antibody by enzyme-linked immunosorbent assay
(ELISA). Sera were diluted 1:1000 (for IgG) or 1:100 (for IgG1,
IgG2a, IgG2b, IgG3) in blocking solution (25% Block Ace
(Dainippon Sumitomo Pharma, Osaka, Japan) in PBS). Then,
96-well plates were coated with 5 mg/ml of recombinant human
GPI for 12 h at 4uC. After washing twice with washing buffer
(0.05% Tween20 in PBS), the blocking solution was applied for
2 h at room temperature to block nonspecific binding. After 2
washes, 150 ml of diluted sera were added, and the plates were
incubated for 2 h at room temperature. After three washes,
horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG
(Dako, Glostrup, Denmark), IgG1 (Rockland, PA), IgG2a, IgG2b,
(Zymed, San Francisco, CA), and IgG3 (Invitrogen) were added at
a final concentration of 1:1000 for 1 h at room temperature. After
three washes, color was developed with TMB microwell perox-
idase substrate (Funakoshi). The optical density was read at
450 nm using a microplate reader.
Measurement of Serum Cytokines
Sera were obtained on days 1, 3, and 6 and analyzed for the
levels of TNF-a and IL-6 by cytometric bead array (CBA) mouse
inflammation kit (BD Biosciences, San Jose, CA) according to the
instructions provided by the manufacturer.
Assessment of Recall Response from Antigen-specific T
cells
Mice were euthanized 6 or 10 days after immunization. The
draining lymph nodes (dLN) and splenocytes were isolated as
described previously [20]. Single-cell suspensions were prepared
in Roswell Park Memorial Institute (RPMI) 1640 medium
(Sigma-Aldrich) containing 10% fetal bovine serum (FBS),
penicillin–streptomycin (100 U/ml), 10 mM HEPES buffer
solution (Gibco BRL, Grand Island, NY), 0.1 mM MEM
nonessential amino acids (Gibco), 1 mM sodium pyruvate
(Gibco), and 5.5 mM 2-mercaptoethanol (2-ME). CD4+ T cells
were isolated from dLN cells by magnetic-activated cell sorting
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). The
purity (more than 95%) was confirmed by flow cytometry.
Splenocytes were incubated with 50 mg/ml mitomycin C
(MMC) (Sigma-Aldrich) for 30 min at 37uC in a water bath.
Figure 2. Expansion of iNKT cells in draining lymph nodes of a-GalCer-treated mice. Mice were immunized with GPI peptide and then
treated with either DMSO or a-GalCer and euthanized on day 6 or 10. The dLNs were obtained and examined for the presence of iNKT cells by FCM
(Data are mean6SD. n = 4–5. Data are representative results of two experiments). (A) iNKT cells were detected as TCRb and a-GalCer-loaded CD1d-
tetramer double positive cells. (B) Proportion of iNKT cells among TCRb+ abT cells, and (C) absolute number of iNKT cells in dLNs of naive or
immunized mice. *p,0.05 by Man-Whitney analysis.
doi:10.1371/journal.pone.0051215.g002
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Purified CD4+ T cells and MMC-treated splenocytes were co-
cultured in the presence of 10 mM of GPI peptide at a ratio of
1:1 for 24 h at 37uC under 5% CO2295% air environment. In
other experiments, MMC-treated non-T cells were used instead
of splenocytes. The supernatants were assayed for IL-17, IFN-c,
IL-2, TNF-a, IL-4 and IL-10 by ELISA using Quantikine
ELISA kit (R&D Systems, Minneapolis, MN).
Statistical Analysis
Values are expressed as mean 6 SD. Differences between
groups were examined for statistical significance using the Man-
Whitney’s U test. Probability values less than 0.05 were considered
significant. All analyses were conducted using The Statistical
Package for Social Sciences software version 19 (SPSS Inc.,
Chicago, IL).
Results
a-GalCer reduces the Severity of GPI Peptide-induced
Arthritis
We first evaluated whether a-GalCer has a protective effect on
GPI peptide-induced arthritis. Mice were intradermally immu-
nized with GPI peptide and treated with either DMSO or a-
GalCer. The severity of arthritis was evaluated by measuring the
clinical score and ankle thickness. The arthritis score on day 14
was significantly lower in a-GalCer-treated mice (3.862.1) than in
control mice (10.761.5, P= 0.004, Fig. 1A and B). Furthermore,
the ankle thickness was significantly less in a-GalCer-treated mice
(3.3460.2 mm) than in control mice (3.9860.26 mm, P=0.008,
Fig. 1A and C). To elucidate whether a-GalCer has protective
effect against arthritis when administered after the initiation of
arthritis, GPI peptide-immunized mice were intradermally
administered with DMSO or a-GalCer on day 10. However,
there was no significant difference between the groups (Fig. S1).
The arthritis scores on day 14 were 9.661.5 in control mice, and
8.661.1 in a-GalCer-treated mice.
a-GalCer Induces iNKT Cell Expansion in Draining Lymph
Nodes
GPI peptide-immunized mice treated with DMSO or a-GalCer
were euthanized on day 6 or 10, and the dLNs were isolated and
prepared for examination of iNKT cells. iNKT cells were
identified as a-GalCer-loaded CD1d-tetramer and TCRb double
positive cells (Fig. 2A). Naive mice were also investigated for the
presence of iNKT cells in the inguinal lymph nodes. The
proportion and absolute number of iNKT cells in the dLNs on
day 6 were significantly higher in the control peptide-treated mice
Figure 3. a-GalCer suppressed the production of autoantibodies against GPI, but not serum inflammatory cytokines. Mice were
immunized with GPI peptide and treated with either DMSO or a-GalCer. Serum samples were obtained on days 1, 3, 6, and 28 after the immunization.
(A) Levels of anti-recombinant human GPI antibody (total IgG, IgG1, IgG2a, IgG2b, IgG3) in sera obtained on day 28 were measured by ELISA (n = 11).
Levels of (B) TNF-a and (C) IL-6 in the sera were measured by CBA (n = 3–5). Data are mean6SD. *p,0.05, by Man-Whitney analysis.
doi:10.1371/journal.pone.0051215.g003
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(0.2260.067%, 9.461.76103 cells, respectively) than in naive
mice (0.08160.018%, 2.661.76103 cells, respectively) (Fig. 2B
and C). Surprisingly, the proportion and absolute number of
iNKT cells in the dLNs were significantly higher in a-GalCer-
treated mice than in control mice both on day 6 (1.160.24%;
P=0.021, 406106103 cells; P = 0.021, respectively) and day 10
(a-GalCer-treated mice: 1.2660.15% and 606176103 cells,
control: 0.06160.017%, 3.061.76103 cells, P = 0.021, respective-
ly (Fig. 2B and C).
Effects of a-GalCer on GPI-specific Antibody Production
To investigate the effects of a-GalCer on GPI-specific antibody
production, serum samples were obtained from control and a-
GalCer-treated mice on day 28 and assayed for the levels of anti-
GPI antibodies by ELISA. Since low levels of anti-GPI antibodies,
especially IgG subtypes, could help identify the type of T helper
cells that mediate the effect of a-GalCer, we also analyzed IgG
subclasses (IgG1, 2a, 2b, 3). Administration of a-GalCer signifi-
cantly reduced the production of anti-GPI antibodies of IgG,
IgG1, and IgG2b compared with the control mice (IgG:
0.1160.087 vs 0.2160.15; P = 0.029, IgG1:0.6860.35 vs
1.160.37; P= 0.014, IgG2b: 0.1360.21 vs 0.3060.35; P = 0.049,
respectively) (Fig. 3A). These results suggest that a-GalCer
suppressed antigen-specific responses independently of subsets of
T helper cells, e.g., Th1 or Th2 cells.
We also analyzed the effects of a-GalCer on inflammatory
cytokines on days 1, 3, and 6. Treatment with a-GalCer did not
alter the serum levels of TNF-a (control: 49614, a-GalCer:
5665.8 pg/ml) and IL-6 (control: 321681, a-GalCer:
309671 pg/ml) measured on day 1 after immunization (Fig. 3B
and C). The levels of these cytokines decreased significantly in
both the DMSO- and a-GalCer-treated mice at day 6, but not at
day 3 (Fig. 3B and C).
Figure 4. Suppression of antigen-specific CD4+ T cells by a-GalCer. (A)(B) Mice were immunized with GPI peptide and treated with either
DMSO or a-GalCer. On day 6 (A) or day 10 (B), mice were euthanized and dLNs and spleens were harvested. CD4+ T cells were isolated from dLNs
using MACS and cultured with mitomycin-treated splenocytes as antigen-presenting cells (APC). After 24-h culture, the levels of IL-17, IFN-c, IL-2, TNF-
a, IL-4 and IL-10 in the supernatant were measured by ELISA (n = 4). (C) Ten days after immunization, the mice were euthanized and dLNs and spleens
were harvested. CD4+ T cells isolated from control or a-GalCer-treated mice were cultured with splenocytes (described as APC in the figure) from
control or a-GalCer-treated mice. Cytokine levels in the culture supernatants were measured by ELISA (n = 4). Data are mean6SD. *p,0.05, by Man-
Whitney analysis.
doi:10.1371/journal.pone.0051215.g004
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Effects of a-GalCer on GPI Peptide-specific Recall
Response of CD4 T cells
The fact that GPI peptide-induced arthritis is T cell dependent,
especially IL-17-producing CD4+ T cells, we also examined the
effects of a-GalCer on antigen-specific CD4+ T cells. To evaluate
antigen-recall response of CD4+ T cells, immunized mice were
euthanized on day 6 or day 10. The isolated CD4+ T cells were
co-cultured with MMC-treated whole splenocytes as APC in the
presence of GPI peptide. Then, the levels of IL-17, IFN-c, IL-2,
TNF-a, IL-4, and IL-10 in the culture supernatants were
measured by ELISA. On day 6, only IL-17 production was
significantly suppressed in a-GalCer-treated mice (control:
15886972 pg/ml, a-GalCer: 5626272 pg/ml; P = 0.028,
Fig. 4A). On day 10, levels of IL-17, IFN-c, IL-2, and TNF-a
were significantly lower in a-GalCer-treated mice than the control
(IL-17:2616110 vs 14436393 pg/ml; P= 0.014, IFN-c: 132682
vs 753661936 pg/ml; P= 0.014, IL-2:141621.5 vs 279647 pg/
ml; P= 0.014, TNF-a: 11.9616.3 vs 185635 pg/ml; P = 0.012,
respectively, Fig. 4B). IL-4 and IL-10 were not detected in this
assay.
To determine the roles of CD4+ T cells and APCs in the above
suppressive effect, CD4+ cells of the DMSO- and a-GalCer-
treated mice were cultured with APCs from control or a-GalCer-
treated mice in the presence of GPI peptide, then analyzed for
cytokine production in response to antigen re-stimulation.
Impaired recall response was noted when CD4+ T cells from a-
GalCer-treated mice were cultured with APCs from control mice
(IL-17:14436393 vs 2036113 pg/ml; P = 0.014, IFN-c:
753661936 vs 66660 pg/ml; P = 0.028, IL-2:279647 vs
125621.5 pg/ml; P= 0.025, TNF-a: 185635 vs 11615 pg/ml;
P= 0.022 in control CD4+control APC and a-GalCer CD4+con-
trol APC group, respectively) (Fig. 4C). On the other hand, no
such impairment of recall response was noted when CD4+ T cells
from control mice were cultured with APCs from a-GalCer-
treated mice (IL-17:11246342 vs 2616110 pg/ml; P = 0.025,
IFN-c: 467461550 vs 132682 pg/ml; P= 0.025, IL-2:21969.2 vs
141622 pg/ml; P= 0.025, TNF-a: 192640 vs 12616 pg/ml;
P= 0.022 in control CD4+a-GalCer APC and a-GalCer CD4+a-
GalCer APC group, respectively) (Fig. 4C). These results suggest
impairment of antigen-specific response in a-GalCer-treated mice
and that CD4+ T cells are responsible for the impairment.
Recall Response of iNKT-depleted CD4+ T cells
Because dLN CD4+ T cells contain approximately 1% of iNKT
cells, we questioned whether the expanding iNKT cells among
dLN CD4+ T cells had direct suppressive effects on antigen-
specific CD4+ T cells. To answer the question, we evaluated the
recall response of iNKT-depleted CD4+ T cells. iNKT-depleted
CD4+ T cells, total CD4+ T cells, and CD3- non-T cells were
sorted from dLN cells of immunized mice on day 10 (Fig. 5A).
These CD4+ T cells were cultured with non-T cells in the
presence of GPI peptide. The production of IL-17 and IFN-c was
suppressed from total CD4+ cells of a-GalCer-treated mice (IL-17:
control: 225637, a-GalCer: 125613 pg/ml; P= 0.014, IFN-c:
control: 3866112, a-GalCer: 81633 pg/ml; P= 0.014) (Fig. 5B).
The production of these cytokine was still suppressed in iNKT-
Figure 5. iNKT cells do not directly suppress antigen-specific CD4+ T cells in vitro. Mice were immunized with GPI peptide and treated with
either DMSO or a-GalCer. Mice were euthanized on day 10 and dLNs were harvested. (A) Total CD4+T cells (CD3+ CD4+ cells) and NKT-depleted
CD4+T cells (CD3+ CD4+ a-GalCer loaded CD1d-tetramer negative cells) were sorted by flow cytometry. These cells were cultured with sorted MMC-
treated CD3-negative cells as APC in the presence of 10 mM of GPI peptide for 24 h. (B) Supernatants were collected and subjects to quantitative
analysis of IL-17 and IFN-c levels by ELISA. Data are mean6SD. (n = 4–5). *p,0.05, **p,0.01, by Man-Whitney analysis.
doi:10.1371/journal.pone.0051215.g005
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depleted CD4+ T cells from a-GalCer-treated mice (IL-17:
control: 219631, a-GalCer: 5564.9 pg/ml; P= 0.014, IFN-c:
control: 3836120, a-GalCer: 83644 pg/ml; P= 0.037) (Fig. 5B).
IL-17 production by GPI reactive T cells was significantly reduced
under iNKT -depleted condition (total CD4+ T cells: 125613,
iNKT-depleted CD4+T cells: 5564.9 pg/ml, P= 0.009)
(Fig. 5B). These results suggest that expanded iNKT cells did
not have direct suppressive effects on antigen-specific CD4+ T
cells in this assay.
Analysis of foxp3+ Regulatory T cells
To determine whether induction of foxp3+ regulatory T cells
mediates the suppressive effect of a-GalCer on antigen-specific
CD4+ cells, we examined dLN cells of immunized mice on days 6
and 10 for the presence of foxp3+ CD25+ TCRb+ T cells by FCM
(Fig. 6A and B). The proportion of foxp3+ T reg cells was
significantly higher in a-GalCer-treated mice than in control mice
on day 6 (control: 5.160.35%, a-GalCer: 5.9360.30%, P= 0.043)
but not on day10 (control: 6.660.62%, a-GalCer: 6.460.48%)
(Fig. 6B). However, based on the small difference, we concluded
that the difference was not the reason for the potent suppressive
effect of a-GalCer on pathogenic CD4+ T cells.
Discussion
GPI-induced arthritis is a newer and closer model of human RA
with regard to its dependency on CD4+ T cells and reactivity to
biological treatments such as blockade of IL-6 and TNF-a, which
are well known to be effective in human RA. Because of its
dependency on T cells, the dominant T cell epitope, which is just
15 mer peptide, can induce arthritis that resembles GPI-induced
arthritis. Although accumulating evidence point to the protective
role of iNKT cells against autoimmune demyelination [6,7], it is
still unclear how iNKT cells work and control autoimmune
arthritis, particularly through their exogenous-ligand activation.
Although iNKT cells are known to promote autoimmune arthritis
such as CIA, collagen-antibody induced arthritis, and K/BxN
serum transfer arthritis [21], they might work differently in a
ligand-specific manner. The present study was designed to explore
the role of a-GalCer in GPI peptide-induced arthritis.
The results demonstrated that a-GalCer potently suppressed the
severity of GPI-peptide induced arthritis. Although the severity of
arthritis on day 10 was not different between the control and a-
GalCer-treated mice, the former group developed more severe
arthritis up to day 14 whereas a-GalCer-treated mice had a milder
form of arthritis. Intradermal administration of a-GalCer with
GPI peptide is delivered into dLNs by dendritic cells (DCs)
residing in the skin and presented to iNKT cells by dLN DCs [22].
These facts mean that iNKT cell proliferated in the dLNs prior to
the onset of arthritis. Hence, we speculated that a-GalCer-
activated iNKT cells regulated GPI-specific immune response
through acquisition of regulatory phenotypes or induction of
regulatory cells, such as T reg cells, as reported in previous studies
[11,12]. However, a-GalCer-activated iNKT cells neither induced
foxp3+ CD25+ regulatory T cells nor had direct regulatory effects
on antigen-specific CD4+ T cells in vitro. Further studies of other T
reg cells might be necessary. Although iNKT cells did not have
direct suppressive effects on differentiated effector T cells, they
might affect helper T cell differentiation in vivo in the induction
phase of arthritis. Oh et al. reported iNKT cells suppress
pathogenic Th17 cells through iNKT cell - T cell interaction
without cytokines in EAE [23]. It is possible that expansion of
Figure 6. a-GalCer does not induce expansion of CD25+foxp3+ regulatory T (Treg) cells. Mice were immunized with GPI peptide and
treated with either DMSO or a-GalCer, then euthanized on day 6 or 10 and dLN cells were harvested. (A) Foxp3+ T reg cells were detected as TCRb,
foxp3- and CD25-positive cells by flow cytometry. (B) Proportion of foxp3+ CD25+ cells among TCRb+ ab T cells. Data are mean6SD. *p,0.05, by
Man-Whitney analysis.
doi:10.1371/journal.pone.0051215.g006
a-GalCer Ameliorates Autoimmune Arthritis
PLOS ONE | www.plosone.org 7 December 2012 | Volume 7 | Issue 12 | e51215
iNKT cells in dLNs enhances the suppression of differentiation of
naive T helper cells into pathogenic effector T cells.
Our previous studies [18,24] demonstrated that immunization
using GPI peptide induced IL-17-producing CD4+ T cells while
blockade of IL-17 resulted in amelioration of arthritis, suggesting
that IL-17-producing CD4+ T cells play a pathogenic role in GPI
peptide-induced arthritis. Since mice deficient in IFN-c receptor
were more resistant to GPI-induced arthritis, IFN-c may also play
a pathogenic role in GPI-induced arthritis [25]. In the present
study, peptide-specific responses were significantly suppressed in a-
GalCer-treated mice on day 10. These results suggest that the
milder form of arthritis in a-GalCer-treated mice could have been
mediated, at least in part, through the suppression of IL-17- and
IFN-c-producing T cells. Kaieda et al. showed that SGL-S23,
an analog of a-GalCer, had suppressive effect on K/BxN serum
transfer arthritis through IFN-c [26]. We previously showed that
a-carba-GalCer, an analog of a-GalCer, suppressed the severity of
CIA through the induction of Th1-biased differentiation of CD4+
T cells [20]. In contrast to these studies, a-GalCer suppressed both
Th1 and Th17 CD4+ T cells in GPI peptide-induced arthritis.
Coppieters et al. reported the proliferation of IL-10-producing
T cells in a-GalCer-treated mice during the course of CIA [9], and
Miellot et al. showed that a-GalCer ameliorated CIA through
the induction of IL-10-producing antigen-specific CD4+ T cells
and that the protective effect was canceled by blockade of IL-10
using anti-IL-10 antibody [8]. Chiba et al. reported the Th2-
polarizing glycolipid ligand of iNKT cells, OCH, had a potent
therapeutic effect against CIA [27]. However, in our study, the
protective effect of a-GalCer against arthritis was not due to the
induction of antigen-specific IL-10 producing cells. Administration
of a-GalCer reduced anti-GPI antibody levels independent of T
helper cell subclasses. These results suggest that a-GalCer
suppressed the whole antigen-specific CD4+ T cells independent
of their subsets (e.g., as Th1, Th2, and Th17). In contrast to the
clear effect of prophylactic administration, therapeutic a-GalCer
administration on day 10 had no effect on the severity of arthritis.
Kim et al. reported activation of iNKT cells by a-GalCer had no
effect on K/BxN serum transfer arthritis in which T and B cells
are not required [28,29]. These facts also suggest that the
suppressive effect of a-GalCer is mediated by regulation of
antigen-specific T cell development.
In conclusion, the present study demonstrated that a-GalCer
significantly suppressed GPI peptide-induced arthritis through the
suppression of antigen-specific CD4+ T cells. Further studies are
needed to determine the mechanism through which a-GalCer-
activated iNKT cells suppress the induction of antigen-specific
CD4+ T cells. Such studies could advance the development of
antigen-specific vaccination therapy against human RA.
Supporting Information
Figure S1 Therapeutic administration of a-GalCer had
no effect on the severity of GPI peptide-induced
arthritis. DBA1 mice were immunized with GPI peptide and
then treated with either DMSO (as a vehicle control) or a-GalCer
on day 10 followed by clinical assessment of arthritis. (n = 5).
Clinical score is shown in the figure. Arrow indicates a-GalCer
administration.
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